Skip to main content

MDB Capital Holdings, LLC

For the period ended Mar 31, 2026. Filed May 14, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 14, 2026

MDBH$1.55+3.3%Stored close · as of Nov 6, 2026

What changed in Management’s Discussion and Analysis?

Read the current filing

Previous report: 10-Q

Period ended 2025-09-30; filed 2025-11-13.

0001493152-25-022351

Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Current report: 10-Q

Period ended 2026-03-31; filed 2026-05-14.

0001493152-26-023080

Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The baseline is this issuer’s latest earlier reporting period of the same form that was filed before the current report. A previous 10-Q is a different quarter, not a year-over-year comparison. Amendments are excluded.

Compared 72 previous paragraphs and 81 current paragraphs.

34 unchanged; 22 reworded; 24 added; 14 removed; 2 previous and 1 current paragraphs rearranged.

Tables are not compared: 11 previous and 7 current tables excluded. Dates, whitespace, punctuation and numbering changes are ignored; changes to financial figures remain significant.

A changed paragraph is not evidence that risk increased or decreased. An unchanged paragraph does not establish that risk stayed the same.

Added paragraphs (24)

Current report

Operating Income. For the three months ended March 31, 2026, operating income was generated from the Company’s fees from investment banking transactions in the broker-dealer and patent related intellectual property services. The increase compared to the three months ended March 31, 2025, is attributable to investment banking activity, as the Company executed a larger transaction in the three months ended March 31, 2026. For the three months ended March 31, 2025, operating income was generated from the Company’s fees from investment banking transactions in the broker-dealer and patent related intellectual property services. The decrease in unrealized loss on investment securities, net (from our licensed broker dealer) was due to a decrease in the market value and fair value of securities held for investment.

Current report

***Other Income.***For the three months ended March 31, 2026, the decrease in other income compared to the three months ended March 31, 2025, was primarily due to mark-to-market losses on securities held outside of the broker-dealer and losses related to dilution from additional equity issuances by eXoZymes. The subordinated loans for the broker-dealer are eliminated for consolidation purposes.

Current report

Income Taxes. For the three months ended March 31, 2026 and 2025, there was no income tax expense.

Current report

Equity Method Investment. For the three months ended March 31, 2026, compared to the three months ended March 31, 2025, the decrease in other income was due to the Company’s recognition of its proportionate share of eXoZymes’ net loss under the equity method of accounting.

Current report

Operating Income. For the three months ended March 31, 2026, operating income was generated from the Company’s fees from investment banking transactions in the broker-dealer and patent related intellectual property services. The increase compared to the three months ended March 31, 2025, is attributable to investment banking activity, as the Company executed a larger transaction in the three months ended March 31, 2026. For the three months ended March 31, 2025, operating income was generated from the Company’s fees from investment banking transactions in the broker-dealer and patent related intellectual property services. The decrease in unrealized loss on investment securities, net (from our licensed broker dealer) was due to mark to market activity in the held securities.

Current report

Technology Segment (MDB Minnesota One). Results of Operations for the Three Months Ended March 31, 2026 and 2025 (in thousands):

Current report

General and Administrative Costs. During the three months ended March 31, 2026 and 2025, there was little activity in this segment and the decrease in professional fees was attributable to less activity and legal fees with M1.

Current report

Stockholders’ equity decreased from December 31, 2025, to March 31, 2026, primarily due to the net loss for the three months ended March 31, 2026, partially offset by the recognition of stock-based compensation expense during the period.

Current report

***Operating Activities.***For the three months ended March 31, 2026, in addition to cash used in normal operating activities, there was an approximately $2.0 million decrease in cash resulting from the release of customer deposits that had been held in segregated accounts in compliance with regulatory requirements at December 31, 2025. These deposits related to an investment banking transaction that closed in early January 2026.

Current report

Investing Activities. There was an investment into the deferred IT costs for development of the self-clearing system, for the three months ended March, 31, 2026. There was no activity for the three months ended March, 31, 2025.

Current report

The Company and its subsidiaries may periodically issue common shares, stock options and restricted stock units to officers, directors, employees, and consultants for services rendered. Options vest and expire according to terms established at the issuance date of each grant. Stock grants, which are generally time vested, are measured at the grant date fair value and charged to operations ratably over the vesting period.

Current report

The Company accounts for stock-based payments to officers, directors, employees, and consultants by measuring the cost of services received in exchange for equity awards utilizing the grant date fair value of the awards, with the cost recognized as compensation expense on the straight-line basis in the Company’s financial statements over the vesting period of the awards.

Current report

The fair value of share options granted as stock-based compensation is determined utilizing the Black-Scholes option-pricing model, and is affected by several variables, the most significant of which are the expected life of the stock option, the exercise price of the share option as compared to the fair market value of the common shares on the grant date, and the estimated volatility of the common shares. Unless sufficient historical exercise data is available, the expected life of the stock option is calculated as the mid-point between the vesting period and the contractual term (the “simplified method”). The estimated volatility is based on the implied volatility by using comparable companies of the Company’s common shares, calculated utilizing a lookback period approximately equal to the contractual life of the stock option being granted. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant. The fair market value of the common shares is determined by reference to the quoted market price of the Company’s common shares on the grant date. The expected dividend yield is based on the Company’s expectation of dividend payouts and is assumed to be zero. The fair value of performance based restricted stock units was determined by using an independent valuation expert.

Current report

On July 1, 2024, MDB Minnesota One (“M1”) entered into a Patent and Know-How License Agreement (the “License Agreement”) with the Mayo Foundation for Medical Education and Research (“Mayo”) for certain patent rights and associated technology pursuant to which M1 intends to develop a small molecule senescence platform. The License Agreement grants M1 rights to develop and commercialize Mayo’s patented technology and know-how for all fields of use on a worldwide basis. Under the terms of the License Agreement, M1 holds an exclusive license of patent rights and a nonexclusive license for the associated technology to make, have made, use, offer for sale, sell, and import licensed products and derivatives.

Current report

As part of initial consideration for the License Agreement, M1 issued 1.98 million shares of common stock equity to Mayo; which at that time represented thirty-three percent of its shares. M1 also paid an initial license fee of $0.15 million as part of the initial consideration. M1 will pay earned royalties on future net sales (including modest minimum annual royalties, which commence in the second year of the term of the License Agreement and gradually increase and plateau over time, and which will be credited against earned royalties due on net sales), and a percentage of any sublicensing income. The earned royalty commences after the first commercial sale of a licensed product. At March 31, 2026, there were no accrued royalties recorded.

Current report

Under the License Agreement, M1 is required to achieve certain development milestones within designated time periods. For select development milestones, as listed below, M1 will be required to make a payment to Mayo, also as noted below:

Current report

● A payment of $0.25 million for Phase II clinical trial initiation, for the first instance of a licensed product.

Current report

● A payment of $1.5 million for Phase III clinical trial initiation, for the first instance of a licensed product.

Current report

● A payment of $2 million for FDA New Drug Application (NDA) acceptance, for the first instance of a licensed product.

Current report

● A payment of $5 million for NDA approval, for each instance of a licensed product.

Current report

As of December 31, 2025, the development milestones noted above are not required to have been met and have not been met. There are other developmental milestones in the License Agreement relating to funding the business and to initiating various clinical trial phases over time.

Current report

M1 is currently in the pre-clinical development stage of the M1 Platform and is undertaking important feasibility studies, iterative testing, and collection of drug safety and toxicity data.
Removed paragraphs (14)

Previous report

Operating Income. For the three-month period ending September 30, 2025 and 2024, there was limited activity, beyond the unrealized gains and losses related to investment securities held. For the nine-month period ending September 30, 2025 and 2024, the Company generated operating income primarily due to investment banking activity completed in February 2025, which was offset by unrealized losses from securities held in the segment.

Previous report

Research and Development Costs. The research and development costs were incurred by the Company’s technology development segment. For the three and nine-months periods ended September 30, 2025, R&D expenses decreased compared to the same period in the prior year, due to the deconsolidation of eXoZymes.

Previous report

***Other Income and Expense.***For the three and nine-month periods ended September 30, 2025, the decrease in other income compared to the same period in the prior year was the result of less interest generated on U.S. Treasury Bill interest from cash used on operating activities during the year. The increase in equity in loss of equity method investee was due to recording the net loss for eXoZymes as equity investee.

Previous report

Operating Income. For the three-month period ending September 30, 2025 and 2024, there was limited activity, beyond the unrealized gains and losses related to investment securities held. For the nine-month period ending September 30, 2025 and 2024, the Company generated operating income primarily due to investment banking activity completed in February 2025, which was offset by unrealized losses from securities held in the segment.

Previous report

General and Administrative Costs. During the three and nine-month periods ended September 30, 2025 and 2024, respectively, several factors contributed to changes in various expense categories:

Previous report

Technology Development Segment (M1 and eXoZymes) Results of Operations for the Three-Months Ended September 30, 2025 and 2024

Previous report

Technology Development Segment (M1 and eXoZymes) Results of Operations for the Nine-Months Ended September 30, 2025 and 2024

Previous report

General and Administrative Costs. During the three and nine-month periods ended September 30, 2025, and 2024, respectively, several factors contributed to changes in various expense categories:

Previous report

Research and Development Costs. The research and development costs were incurred by the Company’s technology development segment. For the three and nine-month periods ended September 30, 2025, R&D expenses decreased compared to the same periods in the prior year, due to the deconsolidation of eXoZymes.

Previous report

The decrease in equity was primarily due from net losses from previous periods.

Previous report

For the nine months ending on September 30, 2024, there was accretion of investments at amortized costs (U.S. Treasury Bills) and the acquisition of investment securities. However, this decrease in cash was partly offset by an increase in accounts payable, grants receivable for the technology segment. Furthermore, clearing deposits, payables to customers, and payables were non-customers all increased due to the implementation of self-clearing operations. There was a decrease in the accrued expenses due to bonuses being paid in Q1 of 2024.

Previous report

Investing Activities. There was a small investment into self-clearing software that is being developed for the nine months ended September 30, 2025. For the nine months ended September 30, 2024, investing activities consisted of the proceeds from the sale and the maturing of U.S. Treasury Bills and purchases of investment securities, which was offset by the reinvestment of the proceeds into new U.S. Treasury Bills and the transfer of cash for operating activities.

Previous report

Technology. Our partner companies’ endeavors to create and bring new technologies to the market may never come to fruition or might not reach a level of development sufficient for commercial viability. Even if they do achieve a commercial level of development, the acceptance of these technologies within the marketplace is uncertain. There’s a possibility that the technologies they develop may not gain widespread or timely acceptance, leading to the necessity for further funding to support the partner companies, or potentially even prompting the difficult choice of discontinuing the business at a financial loss. Moreover, technologies from our partner companies that undergo regulatory scrutiny, testing, and approval may ultimately fail to receive the necessary approvals from relevant regulatory bodies.

Previous report

The requirement to comply with the Uniform Net Capital Rule 15c3-1 may limit Public Ventures’ ability to issue dividends to its parent company.
Reworded paragraphs (22)

Previous wording

Unaudited Condensed Consolidated Results of Operations for the Three-Months Ended September 30, 2025 and 2024

Current wording

Unaudited Condensed Consolidated Results of Operations for the Three Months Ended March 31, 2026 and 2025 (in thousands):

Previous wording

General and Administrative Costs. During the three and nine-month periods ended September 30, 2025 and 2024, respectively, several factors contributed to changes in various expense categories:

Current wording

General and Administrative Costs. During the three months ended March 31, 2026, and 2025, respectively, several factors contributed to changes in various expense categories:

Previous wording

Broker Dealer and Intellectual Property Service Segment (Public Ventures and PatentVest) Results of Operations for the Three-Months Ended September 30, 2025 and 2024

Current wording

Broker Dealer and Intellectual Property Service Segment (Public Ventures and PatentVest) Results of Operations for the Three Months Ended March 31, 2026 and 2025 (in thousands):

Previous wording

Other Income. The decrease in other income for the three and nine-month periods ending September 30, 2025 can be attributed to bank interest income, stemming from a decrease in the cash balances.

Current wording

Other Income. The decrease in other income for the three-month period ending March 31, 2026, can be attributed to interest income, stemming from a decrease in the cash balance from the three-month period ending March 31, 2025.

Previous wording

Operating Income. There was no activity during the three and nine-month periods ended September 30, 2025 and 2024.

Current wording

Operating Income. There was no activity during the three months ended March 31, 2026 and 2025.

Previous wording

Condensed Consolidated Balance Sheets September 30, 2025 and December 31, 2024

Current wording

Condensed Consolidated Balance Sheets March 31, 2026 and December 31, 2025 (in thousands):

Previous wording

Financial Condition: Overall, the reduction in assets was primarily attributed to their utilization for operational activities during the period. The decrease in cash segregated in compliance with regulations stemmed from customer deposits being moved into securities. The drop in investment securities at fair value was due to a decrease in the value of common stock and warrants over the period, offset by the receipt of warrants for investment banking activities. The decrease in prepaid expenses stemmed from usage of prepaid insurance over the period. The increase in accounts receivable is due to an increase in activity from legal and strategy fees. The increase in related party receivable is due to an increase in a loan to an equity method investment. The decrease in equity method investment is directly tied to the Company’s portion of the net loss. Finally, the reduction in property and equipment & right-of-use asset was due to its regular utilization.

Current wording

Financial Condition: Overall, the reduction in assets was primarily attributed to their utilization for operational activities during the period. The decrease in cash segregated in compliance with regulations stemmed from customer deposits held at December 31, 2025, for an investment banking deal that was closing in early January. The decrease in investment securities at fair value was due to a decrease in the value of common stock and warrants over the period offset by the receipt of warrants for investment banking activities. The decrease in prepaid expenses stemmed from the amortization of prepaid insurance over the period. The increase in accounts receivable is due to an increase in activity from legal and strategy fees earned. The increase in related party receivable is due to increased activity by PatentVest for eXoZymes. The decrease in equity method investment is directly tied to the Company’s portion of the net loss. Finally, the reduction in property and equipment and right-of-use assets was due to its regular utilization.

Previous wording

Accounts payable, payables to customers, and related party payables remained stable compared to the previous period. The decrease in accrued expenses stemmed from payments through the normal course of business. Finally, the reduction in lease liability was due to its routine utilization.

Current wording

The increase in accounts payable and accrued expenses stemmed from normal course of business activity. The decrease in payables to customers stemmed from customer deposits. Finally, the reduction in lease liability was due to its routine utilization.

Previous wording

The Company’s unaudited condensed consolidated statements of cash flows as discussed herein are presented below.

Current wording

The Company’s unaudited condensed consolidated statements of cash flows as discussed herein are presented below (in thousands):

Previous wording

At September 30, 2025, the Company had $15,595,859 of working capital. This is a decrease of $3,957,180 from the working capital of $19,553,039 that the Company had at September 30, 2024. The decrease in working capital is primarily attributed to the use of cash to fund operations for the nine-months ended on September 30, 2025.

Current wording

At March 31, 2026, the Company had $14.2 million of working capital. This is a decrease of $5.9 million, from the working capital of $20.1 that the Company had at March 31, 2025. The decrease in working capital is primarily attributed to the use of cash to fund operations.

Previous wording

***Operating Activities.***For the nine months ending September 30, 2025, operating activities use of cash represented a combination of increased activity in the broker dealer, increased professional and consulting fees related to year end audits and issuance of the tax preparation fees related to the publicly traded partnership.

Current wording

For the three months ending on March 31, 2025, operating activities use of cash represented a combination of increased activity in the broker dealer, increased professional and consulting fees related to year end audits and issuance of the tax preparation fees related to the publicly traded partnership.

Previous wording

Financing Activities. There was no activity for the nine months ended September 30, 2025. For the nine months ended September 30, 2024, financing activities consisted of costs related to the deferred costs of the IPO of eXoZymes.

Current wording

Financing Activities. There was no activity for the three months ended March, 31, 2026 and 2025.

Previous wording

The preparation of financial statements in conformity with general accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. We have identified certain accounting policies as being critical because they require us to make difficult, subjective, or complex judgments about matters that are uncertain. We believe that the judgment, estimates, and assumptions used in the preparation of our financial statements are appropriate given the factual circumstances at the time. However, actual results could differ, and the use of other assumptions or estimates could result in material differences in our results of operations or financial condition. Our critical accounting estimates are:

Current wording

The preparation of financial statements in conformity with accounting principles general accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. We have identified certain accounting policies as being critical because they require us to make difficult, subjective, or complex judgments about matters that are uncertain. We believe that the judgment, estimates, and assumptions used in the preparation of our audited consolidated financial statements are appropriate given the factual circumstances at the time. However, actual results could differ, and the use of other assumptions or estimates could result in material differences in our results of operations or financial condition. Our critical accounting estimates are:

Previous wording

The Company receives income from equity underwriting and similar fees. As an underwriter and placement agent, the Company helps clients raise capital via the sale of various types of equity and debt instruments. The fees are primarily based on the issuance price and quantity of the underlying instruments and are recognized as revenue typically upon execution of the client’s transaction. The Company generally does not incur costs to obtain contracts with customers that are eligible for deferral or receive fees prior to recognizing revenue related to investment banking transactions. If the Company did have any contract assets or liabilities related to these revenues it would be recorded on the balance sheets.

Current wording

The Company receives income from underwriting fees. As an underwriter, the Company assists clients to raise capital via the placement of various types of investment securities of private and publicly traded company issuers. Underwriting fees are primarily based on the issuance price and quantity of the underlying instruments and are recognized as revenue typically upon execution of the client’s transaction. The Company generally does not incur costs to obtain contracts with customers that are eligible for deferral or receive fees prior to recognizing revenue related to investment banking transactions. If the Company did have any contract assets or liabilities related to these revenues it would be recorded on the consolidated balance sheets.

Previous wording

On September 20, 2023, the Company completed an initial public offering (IPO), which consisted of the sale of 1,666,666 shares of Class A common shares at $12.00 per share, for gross proceeds of $19,999,992 that was used for the development of eXoZymes, identifying and developing new partner companies, and general corporate and working capital requirements.

Current wording

On September 20, 2023, the Company completed an initial public offering (IPO), which consisted of the sale of 1,666,666 shares of Class A common shares at $12.00 per share, for gross proceeds of $19,999,992 that were used for the development of eXoZymes, identifying and developing new partner companies, and general corporate and working capital requirements.

Previous wording

On June 15, 2022, the Company completed a closing of a private placement, consisting of total gross proceeds of $25,289,660 from the sale of 2,528,966 shares of Class A common shares, which was used for the development of eXoZymes, identifying and developing new partner companies, and general corporate and working capital requirements.

Current wording

On June 15, 2022, the Company completed the closing of a private placement, consisting of total gross proceeds of $25,289,660 from the sale of 2,528,966 shares of Class A common shares, which was used for the development of eXoZymes, identifying and developing new partner companies, and general corporate and working capital requirements.

Previous wording

Potential Recession. There are various indications that the United States economy may be entering a recessionary period. The effect of tariffs imposed by United States and other countries and changing global trade policies should not have a direct effect on the Company but are likely to influence the overall economy. Although unclear at this time an economic recession would likely impact the general business environment and the capital markets, which could, in turn, if there is a recession, such an event could affect the Company.

Current wording

Potential Recession. There are various indications that the United States economy may be entering a recessionary period. The effect of the conflict in the Persian Gulf and world shortages in oil and fertilizer, tariffs imposed by United States and other countries and changing global trade policies should not have a direct effect on the Company but are likely to influence the overall economy. Although it is unclear at this time that an economic recession would likely impact the general business environment and the capital markets, if there is a general global recession that includes the economy of the United States, such an event could affect the Company.

Previous wording

Public Ventures, dba MDB Capital, is subject to the uniform net capital rule (SEC Rule 15c3-1) of the Securities and Exchange Commission (the “SEC”), which requires the maintenance of minimum net capital. At September 30, 2025 and 2024, Public Ventures had net capital of $7,778,582 and $11,765,823, respectively, which was $7,528,582 and $11,515,823 in excess of the minimum $250,000, as required by the Securities and Exchange Commission Rule 15c3-1.

Current wording

Public Ventures, LLC, d/b/a MDB Capital, is subject to the uniform net capital rule (SEC Rule 15c3-1) of the Securities and Exchange Commission (the “SEC”), which requires both the maintenance of minimum net capital and the maintenance of maximum ratio of aggregate indebtedness to net capital. At March 31, 2026 and 2025, Public Ventures had net capital of $10.01 million and $10.18 million, respectively, which was $9.76 and $9.93 million in excess of the minimum $0.25 million, as required by the Securities and Exchange Commission Rule 15c3-1.

Previous wording

In 2024 the Company entered into a subordinated loan agreement with its broker-dealer subsidiary for $7,300,000. This amount, together with existing subordinated loans totaling $5,900,000 and $1,518,257 of accrued interest payable, is subordinated to other liabilities of the Company, and is considered members’ equity for calculating net capital, and is not included in aggregate indebtedness.

Current wording

The Company has subordinated loans with its Parent company totaling $13.2 million and $2.0 million of accrued interest payable, which is subordinated to other liabilities of the Company, and is considered members’ equity for calculating net capital, and is not included in aggregate indebtedness.

Previous wording

Minimum net capital is based upon the greater of the statutory minimum net capital of $250,000 or 2% of customer debits, which was calculated as $0 at September 30, 2025.

Current wording

Minimum net capital is based upon the greater of the statutory minimum net capital of $0.25 million or 2% of aggregate customer debits, which was $0 at March 31, 2026.

Previous wording

To comply with DTC membership requirements, the broker-dealer subsidiary has committed to maintain at least $5,000,000 of net capital in excess of the $250,000 minimum.

Current wording

To comply with to DTCC membership requirements, the Company has committed to maintain at least $5.0 million of net capital in excess of the $0.25 million minimum.

Previous wording

Public Ventures has agreed to indemnify its clearing broker for losses that the clearing broker may sustain from the accounts of customers. Should a customer not fulfill its obligation on a transaction, Public Ventures may be required to buy or sell securities at prevailing market prices in the future on behalf of its customer. The indemnification obligations of Public Ventures to its clearing broker have no maximum amount. All unsettled trades at September 30, 2025 and 2024 have subsequently settled with no resulting material liability to Public Ventures. For the three and nine-months ended September 30, 2025 and 2024 Public Ventures, had no material loss due to counterparty failure and had no obligations outstanding under the indemnification arrangement as of September 30, 2025 and 2024.

Current wording

Public Ventures has agreed to indemnify its clearing broker for losses that the clearing broker may sustain from the accounts of customers. Should a customer not fulfill its obligation on a transaction, Public Ventures may be required to buy or sell securities at prevailing market prices in the future on behalf of its customer. The indemnification obligations of Public Ventures to its clearing brokers have no maximum amount. All unsettled trades at March 31, 2026 and 2025, have subsequently settled with no resulting material liability to Public Ventures. For the years ended March 31, 2026 and 2025, Public Ventures had no material loss due to counterparty failure and had no obligations outstanding under the indemnification arrangement as of March 31, 2026 and 2025.
Rearranged current paragraphs (1)

Current report — wording carried from elsewhere

General and Administrative Costs. During the three months ended March 31, 2026, and 2025, respectively, several factors contributed to changes in various expense categories:
Rearranged previous paragraphs (2)

Previous report — wording carried elsewhere

Unaudited Condensed Consolidated Results of Operations for the Nine-Months Ended September 30, 2025 and 2024

Previous report — wording carried elsewhere

Broker Dealer and Intellectual Property Service Segment (Public Ventures and PatentVest) Results of Operations for the Nine-Months Ended September 30, 2025 and 2024